Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiaohong Wang
Institutions:
People's Hospital of Xinjiang Uygur Autonomous Region,
First Affiliated Hospital of Anhui Medical University
Observed institutions:
Sun Yat-sen University,
Washington University in St. Louis,
People's Hospital of Xinjiang Uygur Autonomous Region,
First Affiliated Hospital of Anhui Medical University,
Third Affiliated Hospital of Sun Yat-sen University,
Alvin J. Siteman Cancer Center
show all 6
ORCID:
0000-0003-1367-9334
Observed ORCID:
0000-0003-1367-9334
OpenAlex ID:
A5006581051
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2023
·
Andrew A. Davis
, Jingqin Luo
, et al.
·
Clinical Cancer Research
·
51
PDF
A Comprehensive Model Outperformed the Single Radiomics Model in Noninvasively Predicting the HER2 Status in Patients with Breast Cancer
2024
·
Weimin Liu
, Yiqing Yang
, et al.
·
Academic Radiology
·
12
Association of LAMA3 expression with perineural invasion and chemoresistance in pancreatic ductal adenocarcinoma
2025
·
Yang Yang
, Yongqiang Chen
, et al.
·
Discover Oncology
·
3
Development and application of an ultra-sensitive ctDNA mutation profiling assay in monitoring therapy response and drug resistance.
2024
·
Tom Zhang
, Harshabad Singh
, et al.
·
Journal of Clinical Oncology
·
1
Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025
·
Andrew A. Davis
, Jingqin Luo
, et al.
Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Chronic ascorbic acid deficiency as a trigger for pseudoexfoliation syndrome: A hypothesis
2025
·
Xiaodi Liu
, Xiaohong Wang
, et al.
·
Medical Hypotheses
Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024
·
Andrew A. Davis
, Jingqin Luo
, et al.
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024
·
Andrew A. Davis
, Jingqin Luo
, et al.
Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024
·
Andrew A. Davis
, Jingqin Luo
, et al.
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024
·
Andrew A. Davis
, Jingqin Luo
, et al.
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024
·
Andrew A. Davis
, Jingqin Luo
, et al.
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024
·
Andrew A. Davis
, Jingqin Luo
, et al.
Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024
·
Andrew A. Davis
, Jingqin Luo
, et al.
Abstract 3663: Extending and analytical validation of a hematological cancer panel for simultaneous detection of driver mutations, copy number variations and translocations in tissue and blood samples
2024
·
Yong Huang
, Tom Zhang
, et al.
·
Cancer Research
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2023
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2023
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2023
·
Andrew A. Davis
, Jingqin Luo
, et al.
Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2023
·
Andrew A. Davis
, Jingqin Luo
, et al.
PDF
Show more works
View as search
Works count:
39
Citation count:
67
H-index:
3
I10-index:
2
Year
Topic
Type